Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Sun Pharma Advanced Research Company Ltd - 532872 - Closure of Trading Window

 This is to inform you that, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and the Code of Conduct for prevention of Insider Trading ('The CoC'), the Trading Window for trading by Designated Persons of the Company and their immediate relatives shall be closed with effect from Wednesday, 1st January 2020 till 48 hours after the declaration of financial results of the Company for the quarter and nine months ended 31st December 2019. The date of Board Meeting for declaration of the financial results for the quarter and nine months ended 31st December 2019 will be intimated in due course. This is for your information and record.
31-12-2019

SPARC signs pact with Bioprojet to acquire exclusive rights for drug to treat auto-immune diseases

 "SPARC... announced that it has entered into an agreement with Bioprojet SCR (Bioprojet) to exclusively acquire Bioprojet's rights to the investigational medicinal product SCD-044," the company said.
19-12-2019
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we enclose herewith the Press Release titled 'SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational Medicinal Product, SCD-044' - which is being released by the Company, which is self-explanatory.
19-12-2019
Bigul

SPARC zooms 6% after US-based firm withdraws patent infringement complaint

 In August this year, Abraxis Biosciences LLC had alleged that SPARC's filing of NDA or Taclantis injection is an act of infringement of the Orange Book listed patents for Abraxane.
09-12-2019
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Update On Taclantis (r)

 pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 and further to our letter No. SPARC/Sec/SE/2019-20/027 dated 20th August 2019 on the subject, we inform you that, Abraxis Biosciences LLC has dismissed the patent infringement complaint filed against SPARC regarding SPARC's New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension). we enclose herewith the Update on the above-mentioned subject being released by the Company, which is self-explanatory. You are requested to kindly take the same on your record & disseminate the information through your website.
09-12-2019
Bigul

Sun Pharma Advanced Research Company Ltd - 532872 - Disclosure Of Related Party Transactions - September 2019

 In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, we hereby submit the Related Party Transactions on consolidated basis, in accordance with the applicable accounting standards, for the half year ended September 30, 2019.
19-11-2019
Bigul

Sun Pharma Advanced Research Company Ltd - 532872 - Disclosure Of Related Party Transactions - September 2019

 In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, we hereby submit the Related Party Transactions on consolidated basis, in accordance with the applicable accounting standards, for the half year ended September 30, 2019.
19-11-2019
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Dear Sir/Madam, Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we enclose herewith the Press Release titled ''SPARC enters into a Licensing Deal with China Medical System Holding Limited (CMS)'' being released by the Company, which is self-explanatory. We request you to kindly take the same on record. Kindly take the above on record.
05-11-2019
Bigul

SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Results For The Quarter And Half Year Ended 30Th September 2019

 The Board of Directors of the Company at their meeting held from 11:30 am to 13:45 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter ended 30th September 2019 which is enclosed herewith along with the Limited Review Report of the Auditors thereon as Annexure I.
04-11-2019
Bigul

Sun Pharma Advanced Research Company Ltd - 532872 - Submission Of Compliance Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

 As per the requirements of Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herewith the Compliance Certificate issued by M/s. Veenit Pal & Associates, Practicing Company Secretaries, for the half year ended 3oth September 2019
22-10-2019
Next Page
Close

Let's Open Free Demat Account